Concurrent Belatacept and Daratumumab Use in Heart Transplant Recipient with Chronic Antibody Mediated Rejection for Medication Adherence. // JHLT Open. – URL: https://www.sciencedirect.com/science/article/pii/S2950133426002600?dgcid=rss_sd_all
Concurrent Belatacept and Daratumumab Use in Heart Transplant Recipient with Chronic Antibody Mediated Rejection for Medication Adherence. JHLT Open. https://www.sciencedirect.com/science/article/pii/S2950133426002600?dgcid=rss_sd_all
“Concurrent Belatacept and Daratumumab Use in Heart Transplant Recipient with Chronic Antibody Mediated Rejection for Medication Adherence.” JHLT Open.
@article{article51048,
title = {Concurrent Belatacept and Daratumumab Use in Heart Transplant Recipient with Chronic Antibody Mediated Rejection for Medication Adherence},
journal = {JHLT Open},
url = {https://www.sciencedirect.com/science/article/pii/S2950133426002600?dgcid=rss_sd_all}
}
Nature Biomedical Engineering, Published online: 18 November 2026; doi:10.1038/s41551-026-01843-z Tumour-associated mucins induce the disassembly of a designer PEGylated paclitaxel-conjugated nanomedicine into small unimers that escape...